Skip to search boxSkip to navigationSkip to main content

Trends in cardiometabolic risk factors in the Americas between 1980 and 2014: A pooled analysis of population-based surveys

  • NCD Risk Factor Collaboration (NCD-RisC) - Americas Working Group
    ,
  • J. Jaime Miranda(corresponding author)(Author)
    ,
  • Rodrigo M. Carrillo-Larco(Author)
    ,
  • Catterina Ferreccio(Author)
    ,
  • Ian R. Hambleton(Author)
    ,
  • Paulo A. Lotufo(Author)
*Corresponding author for this work
  • Universidad Peruana Cayetano Heredia
    ,
  • Imperial College London
    ,
  • Pontificia Universidad Católica de Chile
    ,
  • The University of the West Indies, Cave Hill Campus
    ,
  • University of São Paulo
    ,
  • Miami Veterans Affairs Healthcare System
Research Output:
Contribution to journal
Article
Peer-review

Open access

Publication Information

Output type

Research Output:
Contribution to journal
Article
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages e123-e133

Journal (Volume, Issue Number)

The Lancet Global Health (Volume 8, Issue 1)

Publication milestones

  • Published - 01/2020

Publication status

Published - 01/2020

ISSN

2572-116X

Publication IDs

  • Scopus: 85076249150
  • PubMed: 31839128

Abstract

Background Describing the prevalence and trends of cardiometabolic risk factors that are associated with noncommunicable diseases (NCDs) is crucial for monitoring progress, planning prevention, and providing evidence to support policy efforts. We aimed to analyse the transition in body-mass index (BMI), obesity, blood pressure, raised blood pressure, and diabetes in the Americas, between 1980 and 2014. Methods We did a pooled analysis of population-based studies with data on anthropometric measurements, biomarkers for diabetes, and blood pressure from adults aged 18 years or older. A Bayesian model was used to estimate trends in BMI, raised blood pressure (systolic blood pressure =140 mm Hg or diastolic blood pressure =90 mm Hg), and diabetes (fasting plasma glucose =7.0 mmol/L, history of diabetes, or diabetes treatment) from 1980 to 2014, in 37 countries and six subregions of the Americas. Findings 389 population-based surveys from the Americas were available. Comparing prevalence estimates from 2014 with those of 1980, in the non-English speaking Caribbean subregion, the prevalence of obesity increased from 3.9% (95% CI 2.2-6.3) in 1980, to 18.6% (14.3-23.3) in 2014, in men; and from 12.2% (8.2-17.0) in 1980, to 30.5% (25.7-35.5) in 2014, in women. The English-speaking Caribbean subregion had the largest increase in the prevalence of diabetes, from 5.2% (2.1-10.4) in men and 6.4% (2.6-10.4) in women in 1980, to 11.1% (6.4-17.3) in men and 13.6% (8.2-21.0) in women in 2014). Conversely, the prevalence of raised blood pressure has decreased in all subregions; the largest decrease was found in North America from 27.6% (22.3-33.2) in men and 19.9% (15.8-24.4) in women in 1980, to 15.5% (11.1-20.9) in men and 10.7% (7.7-14.5) in women in 2014. Interpretation Despite the generally high prevalence of cardiometabolic risk factors across the Americas, estimates also showed a high level of heterogeneity in the transition between countries. The increasing prevalence of obesity and diabetes observed over time requires appropriate measures to deal with these public health challenges. Our results support a diversification of health interventions across subregions and countries.

Funding Details

We thank WHO country and regional offices and the World Heart Federation for support in data identification and access. The study was supported by the Wellcome Trust. JJM acknowledges having received support from the Alliance for Health Policy and Systems Research ( HQHSR1206660 ), the Bernard Lown Scholars in Cardiovascular Health Program at Harvard T H Chan School of Public Health ( BLSCHP-1902 ), Bloomberg Philanthropies, FONDECYT via CIENCIACTIVA/CONCYTEC, British Council, British Embassy, and the Newton-Paulet Fund ( 223-2018, 224-2018 ), DFID/MRC/Wellcome Global Health Trials ( MR/M007405/1 ), Fogarty International Center ( R21TW009982, D71TW010877 ), Grand Challenges Canada ( 0335-04 ), International Development Research Center Canada ( IDRC 106887, 108167 ), Inter-American Institute for Global Change Research ( IAI CRN3036 ), Medical Research Council ( MR/P008984/1, MR/P024408/1, MR/P02386X/1 ), National Cancer Institute ( 1P20CA217231 ), National Heart, Lung, and Blood Institute ( HHSN268200900033C, 5U01HL114180, 1UM1HL134590 ), National Institute of Mental Health ( 1U19MH098780 ), Swiss National Science Foundation ( 40P740-160366 ), Wellcome ( 074833/Z/04/Z, 093541/Z/10/Z, 107435/Z/15/Z, 103994/Z/14/Z, 205177/Z/16/Z, 214185/Z/18/Z ), and the World Diabetes Foundation ( WDF15-1224 ). MDC is supported by an Academy of Medical Sciences Springboard Award, and JB by a Royal Society research grant. ME reports a charitable grant from the AstraZeneca Young Health Programme, and personal fees from Prudential, Scor, and Third Bridge, outside of the submitted work. All other authors declare no competing interests. We thank WHO country and regional offices and the World Heart Federation for support in data identification and access. The study was supported by the Wellcome Trust. JJM acknowledges having received support from the Alliance for Health Policy and Systems Research (HQHSR1206660), the Bernard Lown Scholars in Cardiovascular Health Program at Harvard T H Chan School of Public Health (BLSCHP-1902), Bloomberg Philanthropies, FONDECYT via CIENCIACTIVA/CONCYTEC, British Council, British Embassy, and the Newton-Paulet Fund (223-2018, 224-2018), DFID/MRC/Wellcome Global Health Trials (MR/M007405/1), Fogarty International Center (R21TW009982, D71TW010877), Grand Challenges Canada (0335-04), International Development Research Center Canada (IDRC 106887, 108167), Inter-American Institute for Global Change Research (IAI CRN3036), Medical Research Council (MR/P008984/1, MR/P024408/1, MR/P02386X/1), National Cancer Institute (1P20CA217231), National Heart, Lung, and Blood Institute (HHSN268200900033C, 5U01HL114180, 1UM1HL134590), National Institute of Mental Health (1U19MH098780), Swiss National Science Foundation (40P740-160366), Wellcome (074833/Z/04/Z, 093541/Z/10/Z, 107435/Z/15/Z, 103994/Z/14/Z, 205177/Z/16/Z, 214185/Z/18/Z), and the World Diabetes Foundation (WDF15-1224). MDC is supported by an Academy of Medical Sciences Springboard Award, and JB by a Royal Society research grant.
FundersFunding numbers
Bernard Lown Scholars in Cardiovascular Health Program at Harvard T H Chan School of Public Health
BLSCHP-1902
British Embassy
-
Newton-Paulet Fund
224-2018, 223-2018
NIMH
1U19MH098780
NHLBI
5U01HL114180, HHSN268200900033C, 1UM1HL134590
NCI
1P20CA217231
FIC
R21TW009982, D71TW010877
Prudential
-
WHO
-
AHPSR
HQHSR1206660
WT
MR/M007405/1
Bloomberg Philanthropies
-
IDRC
108167, 106887
MRC
MR/P02386X/1, MR/P008984/1, MR/P024408/1
DFID
-
Royal Society
-
British Council
-
Academy of Medical Sciences
-
SNF
107435/Z/15/Z, 205177/Z/16/Z, 40P740-160366, 214185/Z/18/Z, 074833/Z/04/Z, 093541/Z/10/Z, 103994/Z/14/Z
FONDECYT
-
GCC
0335-04
CONCYTEC
-
FONDECYT
-
IAI
IAI CRN3036
WHF
-
WDF
WDF15-1224

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Citations
50
Captures
218
Social media
64

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well